Business Context and Reporting Period
This Form 8-K is filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on May 10, 2017. The filing reports the Company's financial results for the quarter ended March 31, 2017. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific financial figures.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended March 31, 2017, were reported.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, or specific risk factors. It notes that the information furnished, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name is Obalon Therapeutics, Inc., as the input metadata incorrectly listed "Vyome Holdings, Inc."
- Locate and review Exhibit 99.1 (Press Release dated May 10, 2017) to obtain actual revenue, net loss, and cash position figures.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.